EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical outcomes of linezolid-related adverse events in patients with multidrug-resistant TB

T Kodama, Y Sasaki, K Tsuyuguchi, M Okumura, K Kamada, A Yamane, Y Hayashi, E Hagiwara, K Wakamatsu, T Kato, Y Koreeda, K Kuwabara und 7 weitere

The International Journal of Tuberculosis and Lung Disease · 2025

DOI: 10.5588/ijtld.25.0125 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2025. Verfasst von T Kodama und 18 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan;, Department of Basic Mycobacteriosis, Graduate Scho…. Hauptthemen laut MEDLINE: Linezolid, Tuberculosis, Multidrug-Resistant, Antitubercular Agents, Peripheral Nervous System Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND

Linezolid is effective against multidrug-resistant TB (MDR-TB) but is frequently associated with adverse events that limit long-term use. However, data on the clinical outcomes following linezolid-related adverse events among patients with MDR-TB remain limited.





METHODS

This retrospective multicentre study in Japan comprised 81 patients with MDR-TB who developed linezolid-related adverse events during treatment with an initial standard dose of linezolid (600 mg).





RESULTS

Peripheral neuropathy, hematotoxicity, and optic neuropathy were the most frequent adverse events. Most patients with hematotoxicity improved with linezolid discontinuation or dose reduction. However, 20 of 44 patients (45%) with peripheral neuropathy and 2 out of 11 patients (18%) with optic neuropathy did not improve after 1 year of discontinuation. A longer duration from the onset of neuropathy to discontinuation and higher total dosage from the onset to discontinuation were risk factors for both residual peripheral neuropathy and optic neuropathy. Among the patients who discontinued linezolid owing to hematotoxicity, the recurrence rate was 19% (3/16) in those who re-administered linezolid at a low dose (300 mg).





CONCLUSION

If peripheral neuropathy or optic neuropathy occurs, continuous administration of linezolid may lead to long-term residual neuropathies. Re-administration of low-dose linezolid may be considered in cases of hematotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidTuberculosis, Multidrug-ResistantAntitubercular AgentsPeripheral Nervous System DiseasesHumansRetrospective StudiesMaleFemaleMiddle AgedAdultJapanAgedTreatment OutcomeOptic Nerve Diseases

Substanzen

LinezolidAntitubercular Agents

Autor:innen und Institutionen

  • Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan;, Department of Basic Mycobacteriosis, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;, Depa…
  • Center of Pulmonary Disease, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
  • Department of Infectious Diseases, Clinical Research Center, National Hospital Organization Kinki Chuo Chest Medical Center, Sakai, Japan.
  • Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
  • Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan.

Zitieren

APA

Kodama, T., Sasaki, Y., Tsuyuguchi, K., Okumura, M., Kamada, K., Yamane, A., Hayashi, Y., Hagiwara, E., Wakamatsu, K., Kato, T., Koreeda, Y., Kuwabara, K., Amishima, M., Tamaki, S., Takaki, A., Kato, S., Nagai, H., Mitarai, S., & Yoshiyama, T. (2025). Clinical outcomes of linezolid-related adverse events in patients with multidrug-resistant TB. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.25.0125

Vancouver

Kodama T, Sasaki Y, Tsuyuguchi K, Okumura M, Kamada K, Yamane A, et al. Clinical outcomes of linezolid-related adverse events in patients with multidrug-resistant TB. The International Journal of Tuberculosis and Lung Disease. 2025. doi:10.5588/ijtld.25.0125

BibTeX
@article{Kodama2025,
  author = {Kodama, T and Sasaki, Y and Tsuyuguchi, K and Okumura, M and Kamada, K and Yamane, A and Hayashi, Y and Hagiwara, E and Wakamatsu, K and Kato, T and Koreeda, Y and Kuwabara, K and Amishima, M and Tamaki, S and Takaki, A and Kato, S and Nagai, H and Mitarai, S and Yoshiyama, T},
  title = {Clinical outcomes of linezolid-related adverse events in patients with multidrug-resistant TB},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2025},
  doi = {10.5588/ijtld.25.0125}
}
Kostenlos starten →